Brain Oligometastasis in NSCLC

N/AActive Not RecruitingNCT07389642

University Hospital, Bordeaux46 enrolled

Overview

75-80% of NSCLC are diagnosed at the metastatic stage. Among the most frequent sites are brain metastases. The management of patients with exclusive limited brain involvement is not standardized. The question is therefore which therapeutic strategy is optimal in such disease presentation. We will analyze the impact of different therapeutic strategies on patients treated at Bordeaux University Hospital and the Bergonié Institute

75-80% of NSCLC are diagnosed at the metastatic stage. Among the most frequent sites are brain metastases. The management of patients with exclusive limited brain involvement is not standardized. The question is therefore which therapeutic strategy is optimal in terms of disease control: local treatment of the main tumor and brain versus systemic treatment with chemotherapy and immunotherapy. We will analyze the impact of these 2 strategies on patients treated at Bordeaux University Hospital and the Bergonié Institute.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Brain Oligometastatic Non-small Cell Lung Cancer

Interventions

Standard treatments / multiple strategiesOTHER

Standard treatments / multiple strategies

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Consecutive patients managed at Bordeaux University Hospital * Non-small-cell lung cancer * Oligometastatic brain cancer (fewer than 5 lesions at diagnosis) * Patient over 18 years old Exclusion Criteria: * Oncogenic addiction EGFR, ALK, ROS1 * Patient with concomitant cancer * Patient with prior treatment for lung cancer in the year preceding diagnosis at metastatic stage

Locations (1)

CHU de Bordeaux

Bordeaux, France

Outcomes

Primary Outcomes

Progression free survival (PFS)

Time from random assignment in a clinical trial to disease progression or death from any cause

Time frame: Once, at progression or death from any cause

Secondary Outcomes

PFS from the date of the next treatment to disease progression or death from any cause (PFS2)

PFS from the date of the next treatment to disease progression or death from any cause

Time frame: Once, at progression or death from any cause

Overall survival (OS)

Time from either the date of diagnosis or the start of treatment for a disease, such as cancer, that patients diagnosed with the disease are still alive

Time frame: Once, death from any cause or lost of follow-up

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.